CAM
PDLI

Capstone Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Capstone Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-16,443
Closed -$131K – 2068
2013
Q3 		$131K Sell
16,443
-100
-0.6% -$804 ﹤0.01% 1920
2013
Q2 		$128K Buy
+16,543
New +$129K ﹤0.01% 1871

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Gotham Asset Management
Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return
Advisors Asset Management
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

Capstone Asset Management's PDLI Position: Q4 2013 in Review

Capstone Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2013, closing a stake of 16,443 shares — an estimated $131K sold.

Capstone Asset Management first reported a position in PDLI in Q2 2013 and held it in 2 quarters. The position peaked at $131K in Q3 2013. 224 funds tracked by Wall St. Rank hold PDLI as of Q4 2013.

  • Capstone Asset Management reported no remaining PDL BioPharma, Inc. position as of Q4 2013 after selling out during the quarter.
  • Capstone Asset Management sold 16,443 PDL BioPharma, Inc. shares in Q4 2013, an estimated $131K.
  • Capstone Asset Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 2 quarters.
  • Capstone Asset Management's PDL BioPharma, Inc. position peaked at $131K in Q3 2013.
  • 224 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2013.

Based on Capstone Asset Management's 13F filing for Q4 2013, filed 4 Feb 2014.